Loading clinical trials...
Loading clinical trials...
Discover 19,983 clinical trials near Maryland. Find research studies in your area.
Showing 12341-12360 of 19,983 trials
NCT02215967
Background: \- T cells are white blood cells that fight several cancers. One cancer therapy involves removing a persons' T cells, changing them in a lab, and then returning them to the person. Researchers want to see if this helps people with multiple myeloma. Objective: \- To test the safety of giving anti-B-Cell Maturation Antigen T cells to people with multiple myeloma. Eligibility: \- Adults ages 18-70 with multiple myeloma that has not responded to standard therapies. Design: * Participants may be screened with: * Medical history * Physical exam * Blood and urine tests * Heart tests * Bone marrow sample * Multiple scans and X-rays * Participants will have apheresis. Blood is removed through a needle in an arm. T cells are removed. The rest of the blood is returned through a needle in the other arm. * The cells will be changed in a laboratory. * Participants will get 2 chemotherapy drugs over 3 days. * Two days later, participants will check into the hospital. They will get an intravenous (IV) catheter in an arm or chest vein. They will get the T cells through the IV in 1 infusion. * After this, participants will stay in the hospital for at least 9 days and stay nearby for 2 weeks. Then they will have blood tests and see a doctor. * Participants will visit the clinic 1, 2, 3, 4, 6, and 12 months after the infusion, then every 6 months. A bone marrow sample will be taken at the 2-month visit. * Participants blood will be collected for several years. Participants will have an annual physical at National Institutes of Health (NIH) for 5 years after the infusion. Then for 10 years they will answer health questionnaires.
NCT01806909
Background: * Adenoviruses are viruses that typically cause symptoms of a cold or eye infection. These viruses are being tested as part of a possible new vaccine. Researchers hope that the adenovirus will help carry the vaccine into the body and cause an immune response. An immune response is the body s release of cells and substances that protect the body from infection. If an adenovirus vaccine can be developed, it might be used as part of a vaccine for malaria or other serious illnesses. Researchers want to test the adenovirus vaccine as a nasal spray in healthy volunteers. The vaccine is called AD4-H5-VTN. * Because the vaccine contains a live adenovirus, there is a possibility that participants can infect other people. Therefore, participants' intimate contacts must join this study. An intimate contact is someone who the participant will kiss on the mouth or have sexual intercourse with during the period of this study. Objectives: * To study the immune response of the AD4-H5-VTN vaccine in healthy volunteers. * To see if the adenovirus in the AD4-H5-VTN vaccine is contagious or spreads to others. Eligibility: * Healthy volunteers between 18 and 49 years of age. * Intimate contacts of healthy volunteers between 18 and 65 years of age. * Participants must not have evidence of previous exposure to adenovirus type 4. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants who will receive the vaccine must be willing to be hospitalized for between 5 and 7 days. They will come to the National Institutes of Health for follow-up visits weekly for the first month, after 8 weeks, in 6 months, and possibly 1 year. They must also avoid all vaccines (including seasonal flu vaccine) and allergy shots for 30 days before and after having the study vaccine. * Participants will enter the hospital for the vaccine study visit. They will receive the vaccine as a nasal spray. Because the vaccine uses a live virus, participants may be contagious for the virus for up to 4 weeks. They will remain in the hospital in respiratory isolation for 7 days, or until they have two negative nasal washes taken 1 day apart. A negative nasal wash means that there is no live virus in the nose. * After leaving the hospital, participants will keep a diary at home for at least 3 weeks. They will record their temperature, any symptoms, or other health changes every day during this time. * Participants should avoid intimate contact with others for 28 days after having the vaccine. Intimate contact includes kissing on the mouth and sexual intercourse. Also, participants should not share kitchen utensils, drinking cups, towels, or hair combs with others. Intimate contacts will also keep track of any illnesses or symptoms they develop during this time. * At the follow-up visits, participants will provide blood and swab samples for study.